More

    Bharat Biotech starts human trial for COVAXIN

    Must Read

    Vadodara traders appeal to close down markets in the evening to stop transition of Corona

    The Vadodara Trade Development Association has appealed to the mayor and police commissioner to close Vadodara markets...

    Bombay high court to hear Rhea Chakraborty’s bail plea today

    The Bombay high court will take up the bail applications filed by Rhea Chakraborty and her brother...

    Family of deceased demand compensation held contractor responsible for the incident

    Three people died in Vadodara after a three storey under construction building in Bawamanpura collapsed late last...

    The human trial of Bharat Biotech’s anti-COVID-19 vaccine Covaxin began at Rohtak’s Post-Graduate Institute of Medical Sciences on Friday, Haryana Health Minister Anil Vij said.

    The minister also said the vaccine has been administered to three persons who have shown no adverse effect to it.

    Doctors at the Rohtak PGIMS, meanwhile, told reporters that three volunteers were administered the vaccine as part of the first phase of the clinical trial.

    They said the process might take six months, but over the next two-three months, the effect of the vaccine would be assessed from the antibodies generated and any adverse reaction caused, if any.

    The volunteers are in the age group of 30 to 40 years.

    The vaccine will now be administered to ten persons who like the three would be observed on a regular basis.

    In the second phase, more vaccine candidates will be enrolled and the vaccine dosage would also be increased, they said.

    Bharat Biotech got the country’s drug regulator’s approval to start clinical trials of its anti-Corona vaccine Covaxin recently.

    There are over seven anti-corona vaccines at various stages of development in the country with two of them having received the drug regulator’s go-ahead to start the human clinical trials of their vaccines.

    Earlier on Wednesday, drug firm Zydus had said it has started human clinical trials of its COVID-19 vaccine candidate ZyCoV-D. In this phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India, it had said in a regulatory filing.

    Zydus had got the approval a few days after India’s first indigenous COVID-19 vaccine candidate COVAXIN, developed by Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology, got the nod for human clinical trials from the Drug Controller General of India.

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    Latest News

    Bombay high court to hear Rhea Chakraborty’s bail plea today

    The Bombay high court will take up the bail applications filed by Rhea Chakraborty and her brother...

    Bombay high court to hear Rhea Chakraborty’s bail plea today

    The Bombay high court will take up the bail applications filed by Rhea Chakraborty and her brother Showik Chakraborty on Tuesday. Both...

    Family of deceased demand compensation held contractor responsible for the incident

    Three people died in Vadodara after a three storey under construction building in Bawamanpura collapsed late last night. The family members held...

    Two children orphaned after the young couple died in building collapse in Vadodara

    A young couple died after a three storey building in Bawamanpura in Vadodara collapsed late night on Monday. The incident left their...

    Home Ministry sanctions three new NIA branches at Imphal, Chennai, Ranchi

    National Investigation Agency (NIA) will have three more branches in Imphal, Chennai and Ranchi. Union Home Ministry has sanctioned three new NIA...

    More Articles Like This

    - Advertisement -